



3rd April 2025

Cambridge Cognition Holdings plc
("Cambridge Cognition", the "Company" or the "Group")

Contract Win

Cambridge Cognition selected for two Phase 3 trials combining digital cognitive and voice solutions

Cambridge Cognition (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment, has been selected by a major pharmaceutical company to provide digital cognitive and voice assessments for two Phase 3 clinical trials in adolescents with Major Depressive Disorder (MDD). Both contracts are set to commence this year, with the first running until 2027 and the second through to 2029. The total value of the combined contracts is estimated at approximately £1.2 million.

MDD among adolescents represents a critical public health challenge with significant long-term implications¹. The past three years have witnessed a substantial 30% growth in industry-sponsored clinical studies focused on depression², highlighting an increasing research commitment to mental health interventions. The market for MDD is expected to exceed 19 billion by 2030³.

Cambridge Cognition has been selected as a strategic partner to advance clinical trial methodologies through innovative speech analysis. By integrating speech biomarkers with cognitive assessments, the platform enables more precise patient monitoring, allowing researchers to capture nuanced treatment-response insights. Additionally, the inclusion of cognitive assessments will enable detection of improvements in cognitive function, which is frequently impaired in depression and closely linked to overall functioning.

Rob Baker, Joint Managing Director and Chief Operating Officer, commented:

"This strategically important contract win highlights the value of our integrated speech and cognitive platform that not only delivers robust and reliable results for the pharmaceutical company but also reduces trial costs and patient burden. As a result, we see significant future demand for our unique platform, and we remain confident in our ambitions to significantly grow sales in the high-impact, late-stage CNS trials market over the coming years."

1. Thapar, A., Collishaw, S., Pine, D. S., & Thapar, A. K. (2012). Depression in adolescence. *The Lancet*, 379(9820), 1056-1067.
2. Data sourced from Citeline's Trial Trove, Informa Pharma Intelligence, accessed March 2025
3. Anxiety Disorders And Depression Treatment Market Size, Share & Trends Analysis Report By Drug Type, By Indication (Depression, Anxiety), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030. Grand View Research

Enquiries:

Cambridge Cognition Holdings plc Rob Baker, Joint Managing Director and Chief Operating Officer	Tel: 012 2381 0700 press@camcog.com
Panmure Liberum Limited (NOMAD and Joint Broker) Freddy Crossley / Will Goode / Mark Rogers Rupert Dearden	Tel: 020 7886 2968 (Corporate Finance) (Corporate Broking)
Dowgate Capital Limited (Joint Broker) David Poutney / James Serjeant	Tel: 020 3903 7715
Hudson Sandler (Financial PR and IR) Dan de Belder / Hattie Dreyfus / Harry Griffiths	Tel: 020 7796 4133 cog@hudsonsandler.com

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a brain health software group specializing in digital health products that advance brain health research and treatment. The company offers four core products: CANTAB® assessments-providing scientifically validated, highly sensitive, precise, and objective measures of cognitive function correlated to neural networks; a flexible and proven eCOA platform with an extensive library of instruments, enabling efficient study setup and scalable data capture; rater training services that standardise assessment delivery and scoring across clinical trials and quality assurance tools that ensure data integrity by

automatically detecting deviations in administration and scoring, saving time and money. These products collectively improve clinical trial outcomes, enable early patient identification, and enhance global efficiency in healthcare and pharmaceuticals.

For further information, visit: www.cambridgecognition.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

CNTUUSKRVRUSRAR